首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Network Pharmacology-Based Strategy to Investigate the Pharmacological Mechanisms of Ginkgo biloba Extract for Aging
【24h】

Network Pharmacology-Based Strategy to Investigate the Pharmacological Mechanisms of Ginkgo biloba Extract for Aging

机译:基于网络药理学的策略,探讨Ginkgo Biloba提取物的药理机制

获取原文
           

摘要

Aging is a main risk factor for a number of debilitating diseases and contributes to an increase in mortality. Previous studies have shown that Ginkgo biloba extract (EGb) can prevent and treat aging-related diseases, but its pharmacological effects need to be further clarified. This study aimed to propose a network pharmacology-based method to identify the therapeutic pathways of EGb for aging. The active components of EGb and targets of sample chemicals were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database. Information on aging-related genes was obtained from the Human Ageing Genomic Resources database and JenAge Ageing Factor Database. Subsequently, a network containing the interactions between the putative targets of EGb and known therapeutic targets of aging was established, which was used to investigate the pharmacological mechanisms of EGb for aging. A total of 24 active components, 154 targets of active components of EGb, and 308 targets of aging were obtained. Network construction and pathway enrichment were conducted after data integration. The study found that flavonoids (quercetin, luteolin, and kaempferol) and beta-sitosterol may be the main active components of EGb. The top eight candidate targets, namely, PTGS2, PPARG, DPP4, GSK3B, CCNA2, AR, MAPK14, and ESR1, were selected as the main therapeutic targets of EGb. Pathway enrichment results in various pathways were associated with inhibition of oxidative stress, inhibition of inflammation, amelioration of insulin resistance, and regulation of cellular biological processes. Molecular docking results showed that PPARG had better binding capacity with beta-sitosterol, and PTGS2 had better binding capacity with kaempferol and quercetin. The main components of EGb may act on multiple targets, such as PTGS2, PPARG, DPP4, and GSK3B, to regulate multiple pathways, and play an antiaging role by inhibiting oxidative stress, inhibiting inflammation, and ameliorating insulin resistance.
机译:老化是一些衰弱疾病的主要风险因素,有助于增加死亡率。以前的研究表明,银杏叶提取物(EGB)可以预防和治疗衰老相关疾病,但需要进一步澄清其药理效应。本研究旨在提出一种基于网络药理学的方法,以鉴定EGB用于老化的治疗途径。从中医系统药理学数据库和分析平台(TCMSP)数据库中获得EGB的活性成分和样品化学品的靶标。从人衰老基因组资源数据库和JENAGE老化因子数据库中获得了相关基因的信息。随后,建立了含有EGB的推定靶标的相互作用和已知的老化治疗靶标的网络,用于研究EGB用于老化的药理学机制。获得总共24种活性组分,154个EGB的活性组分的靶标和308次衰老靶标。网络建设和途径富集在数据集成后进行。该研究发现,黄酮类化合物(槲皮素,叶氏菌苷酸和Kaempferol)和β-谷甾醇可以是EGB的主要活性组分。选择前八个候选靶,即PTGS2,PPARG,DPP4,GSK3B,CCNA2,AR,MAPK14和ESR1作为EGB的主要治疗靶标。途径富集在各种途径中导致抑制氧化应激,抑制炎症,胰岛素抵抗力的抑制,以及细胞生物学过程的调节。分子对接结果表明,PPARG与β-谷甾醇具有更好的结合能力,PTGS2具有更好的结合能力与Kaempferol和槲皮素具有更好的结合能力。 EGB的主要成分可以在多个靶标上作用,例如PTGS2,PPARG,DPP4和GSK3B,以调节多种途径,并通过抑制氧化应激,抑制炎症和改善胰岛素抵抗来发挥抗衰率作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号